Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, and WuXi XDC, a leading global CRDMO, joint announced that they have signed a LOI for long-term strategic collaboration on Mabwell’s multiple ADC projects.

Mabwell has had multiple innovative products in clinical studies or preclinical research by their world-leading ADC technology platforms and CMC development capabilities. WuXi XDC will make further efforts to accelerate global layout of Mabwell’s R&D and commercialization, cost reduction and R&D efficiency improvement by their leading antibody-drug conjugate production technology platform and integration capabilities.